GlobeNewswire Inc.Jun 17, 11:02 PM ET▼ Negative
The company is the subject of a fiduciary duty investigation regarding a private placement transaction, suggesting potential mismanagement or breach of stockholder trust by the board of directors.
Indaptus Therapeutics news
$2.85−13.37%
Close Sep 29, 2026 · split-adjustedArticles · 30 days0English, de-duplicated
Positive0
Neutral0
Negative0
About Indaptus Therapeutics
Also mentions INDP
Articles that tag INDP but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology